Patents by Inventor Ferdinando PUCCI

Ferdinando PUCCI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230048166
    Abstract: The present disclosure provides, at least in part, methods and compositions for in vivo fusosome delivery. In some embodiments, the fusosome comprises a combination of elements that promote specificity for target cells, e.g., one or more of a fusogen, a positive target cell-specific regulatory element, and a non-target cell-specific regulatory element. In some embodiments, the fusosome comprises one or more modifications that decrease an immune response against the fusosome.
    Type: Application
    Filed: November 14, 2019
    Publication date: February 16, 2023
    Inventors: Geoffrey A. von Maltzahn, Jacob Rosenblum Rubens, Jagesh Vijaykumar Shah, Albert Ruzo Matias, Ferdinando Pucci, John Miles Milwid, Michael Travis Mee, Neal Francis Gordon
  • Publication number: 20230043255
    Abstract: The present disclosure provides, at least in part, methods and compositions for in vivo fusosome delivery. In some embodiments, the fusosome comprises a combination of elements that promote specificity for target cells, e.g., one or more of a fusogen, a positive target cell-specific regulatory element, and a non-target cell-specific regulatory element. In some embodiments, the fusosome comprises one or more modifications that decrease an immune response against the fusosome.
    Type: Application
    Filed: November 14, 2019
    Publication date: February 9, 2023
    Inventors: Geoffrey A. von Maltzahn, Jacob Rosenblum Rubens, Jagesh Vijaykumar Shah, Albert Ruzo Matias, Ferdinando Pucci, John Miles Milwid, Michael Travis Mee, Neal Francis Gordon
  • Patent number: 11472856
    Abstract: The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and/or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: October 18, 2022
    Assignee: Torque Therapeutics, Inc.
    Inventors: Ferdinando Pucci, Thomas Lars Andresen, Douglas Scott Jones, Ulrik Nielsen, James Andrew Rakestraw
  • Publication number: 20220008557
    Abstract: The present disclosure provides, at least in part, methods and compositions for in vivo fusosome delivery. In some embodiments, the fusosome comprises a combination of elements that promote specificity for target cells, e.g., one or more of a fusogen, a positive target cell-specific regulatory element, and a non-target cell-specific regulatory element. In some embodiments, the fusosome comprises one or more modifications that decrease an immune response against the fusosome.
    Type: Application
    Filed: November 14, 2019
    Publication date: January 13, 2022
    Inventors: Geoffrey A. von Maltzahn, Jacob Rosenblum Rubens, Jagesh Vijaykumar Shah, Albert Ruzo Matias, Ferdinando Pucci, John Miles Milwid, Michael Travis Mee, Neal Francis Gordon
  • Publication number: 20200131239
    Abstract: The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and/or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.
    Type: Application
    Filed: June 13, 2017
    Publication date: April 30, 2020
    Applicant: Torque Therapeutics, Inc.
    Inventors: Ferdinando PUCCI, Thomas Lars ANDRESEN, Douglas Scott JONES, Ulrik NIELSEN, James Andrew RAKESTRAW